Teladoc Health, INC Form 4 insider transactions

Adam Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units, between March 1 and March 4, 2024.

Teladoc Health's CEO, Jason Gorevic, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units.

Chief Technology Officer Nikolaos P. Nanis of Teladoc Health, Inc. reports acquisition and disposal of common stock and derivative securities.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units, in recent transactions.

EVP Andrew Turitz of Teladoc Health reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units, through both market sales and vesting events.

Daniel Trencher, Chief Strategy Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units, in a recent SEC filing.

Mala Murthy, CFO of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units, in a recent SEC Form 4 filing.

Arnnon Geshuri, Chief People Officer of Teladoc Health, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and performance stock units, in recent transactions.

Arnnon Geshuri, Chief People Officer of Teladoc Health, sold 404 shares of common stock on February 26, 2024, at a price of $14.503 per share to cover tax withholding obligations related to vesting restricted stock units.